TR201909923T4 - Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. - Google Patents
Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. Download PDFInfo
- Publication number
- TR201909923T4 TR201909923T4 TR2019/09923T TR201909923T TR201909923T4 TR 201909923 T4 TR201909923 T4 TR 201909923T4 TR 2019/09923 T TR2019/09923 T TR 2019/09923T TR 201909923 T TR201909923 T TR 201909923T TR 201909923 T4 TR201909923 T4 TR 201909923T4
- Authority
- TR
- Turkey
- Prior art keywords
- prevention
- treatment
- kidney disease
- composition containing
- pyrazole derivative
- Prior art date
Links
- 208000017169 kidney disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120093936A KR101633957B1 (ko) | 2012-08-27 | 2012-08-27 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201909923T4 true TR201909923T4 (tr) | 2019-07-22 |
Family
ID=50183832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/09923T TR201909923T4 (tr) | 2012-08-27 | 2013-08-02 | Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10047067B2 (enExample) |
| EP (1) | EP2889032B1 (enExample) |
| JP (1) | JP5974180B2 (enExample) |
| KR (1) | KR101633957B1 (enExample) |
| CN (1) | CN104755077B (enExample) |
| ES (1) | ES2734264T3 (enExample) |
| PL (1) | PL2889032T3 (enExample) |
| TR (1) | TR201909923T4 (enExample) |
| WO (1) | WO2014035070A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101826208B1 (ko) | 2016-02-05 | 2018-02-06 | 경북대학교 산학협력단 | 뉴로펩타이드 y를 유효성분으로 포함하는, 신장질환의 예방 또는 치료용 약학적 조성물 |
| KR101856444B1 (ko) * | 2017-04-20 | 2018-05-10 | 압타바이오 주식회사 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| WO2021101344A1 (ko) | 2019-11-21 | 2021-05-27 | 삼진제약주식회사 | 안질환 예방 또는 치료용 점안 조성물 |
| KR102277665B1 (ko) * | 2020-02-05 | 2021-07-15 | 바이오그래핀 주식회사 | 그래핀 기반 신장 질환 치료용 조성물 |
| US20230201179A1 (en) * | 2020-04-08 | 2023-06-29 | Aptabio Therapeutics Inc. | Agent for treating contrast-induced acute kidney injury |
| KR102308991B1 (ko) * | 2020-04-08 | 2021-10-06 | 압타바이오 주식회사 | 조영제 유발 급성 신부전 치료제 |
| CN115427039B (zh) * | 2020-04-13 | 2025-04-04 | 阿普塔生物治疗公司 | 包含吡唑衍生物的肺纤维化药物 |
| KR102386097B1 (ko) * | 2020-04-13 | 2022-04-14 | 압타바이오 주식회사 | 피라졸 유도체의 폐섬유증 치료제 |
| JP2023553010A (ja) | 2020-12-03 | 2023-12-20 | バテル・メモリアル・インスティテュート | 非ウイルス性送達のためのポリマーナノ粒子およびｄｎａナノ構造組成物ならびに方法 |
| KR102589130B1 (ko) * | 2021-03-24 | 2023-10-13 | 삼진제약주식회사 | N-옥소 피리딘 화합물 발생을 억제하는 안질환 예방 또는 치료용 점안 조성물 |
| EP4320233A4 (en) | 2021-04-07 | 2025-08-13 | Battelle Memorial Institute | RAPID DESIGN, BUILD, TEST, AND LEARNING TECHNOLOGIES TO IDENTIFY AND USE NON-VIRAL VECTORS |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| CN119504599B (zh) * | 2024-11-18 | 2025-09-26 | 安徽医科大学 | 一种用于治疗肾脏纤维化的吡唑类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4023488A1 (de) | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
| AU2697092A (en) | 1991-10-08 | 1993-05-03 | Nippon Soda Co., Ltd. | Pyrazole derivative and agrohorticultural bactericide containing same |
| JP2003098120A (ja) | 2001-09-26 | 2003-04-03 | Tokyo Weld Co Ltd | 外観検査装置 |
| JP4189850B2 (ja) * | 2002-05-20 | 2008-12-03 | 味の素株式会社 | 線維化病変組織修復剤 |
| KR20040094464A (ko) * | 2003-05-02 | 2004-11-10 | 학교법인 이화학당 | 피리디닐 피라졸 유도체 |
| EP1900728A1 (en) * | 2005-05-30 | 2008-03-19 | Genecare Research Institute Co., Ltd | Pharmaceutical composition comprising pyrazolone derivative |
| WO2008026658A1 (ja) * | 2006-09-01 | 2008-03-06 | Otsuka Chemical Co., Ltd. | Ｎ－ピリジルピペリジン化合物、その製造方法及び有害生物防除剤 |
| KR100942382B1 (ko) | 2008-03-25 | 2010-02-12 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 골다공증 예방 및 치료용 조성물 |
| US8637674B2 (en) | 2009-09-02 | 2014-01-28 | Ewha University-Industry Collaboration Foundation | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same |
| WO2011028043A2 (ko) * | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
-
2012
- 2012-08-27 KR KR1020120093936A patent/KR101633957B1/ko active Active
-
2013
- 2013-08-02 EP EP13834243.1A patent/EP2889032B1/en active Active
- 2013-08-02 US US14/424,771 patent/US10047067B2/en active Active
- 2013-08-02 TR TR2019/09923T patent/TR201909923T4/tr unknown
- 2013-08-02 PL PL13834243T patent/PL2889032T3/pl unknown
- 2013-08-02 WO PCT/KR2013/006985 patent/WO2014035070A1/ko not_active Ceased
- 2013-08-02 JP JP2015529664A patent/JP5974180B2/ja active Active
- 2013-08-02 CN CN201380056244.5A patent/CN104755077B/zh active Active
- 2013-08-02 ES ES13834243T patent/ES2734264T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104755077A (zh) | 2015-07-01 |
| WO2014035070A1 (ko) | 2014-03-06 |
| ES2734264T3 (es) | 2019-12-05 |
| JP5974180B2 (ja) | 2016-08-23 |
| KR101633957B1 (ko) | 2016-06-27 |
| US10047067B2 (en) | 2018-08-14 |
| JP2015531774A (ja) | 2015-11-05 |
| CN104755077B (zh) | 2018-05-15 |
| KR20140027833A (ko) | 2014-03-07 |
| EP2889032A1 (en) | 2015-07-01 |
| EP2889032A4 (en) | 2016-03-09 |
| US20150218125A1 (en) | 2015-08-06 |
| EP2889032B1 (en) | 2019-05-08 |
| PL2889032T3 (pl) | 2019-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201909923T4 (tr) | Böbrek hastalığının önlenmesi ya da tedavisi için pirazol türevini ihtiva eden kompozisyon. | |
| JOP20180103A1 (ar) | مركب صيدلاني | |
| CY1121497T1 (el) | Συριγγα | |
| EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
| EA201590321A1 (ru) | Дейтерированный барицитиниб | |
| MY173843A (en) | Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents | |
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
| EA201590887A1 (ru) | Композиция | |
| EA201290642A1 (ru) | Соединения и способы | |
| BR112015001697A2 (pt) | formulações de clomazona | |
| EA201590962A1 (ru) | Новые соединения | |
| EA201591451A1 (ru) | Модуляторы flap | |
| EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
| MX349224B (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa. | |
| UA115135C2 (uk) | Катіонні полімери на основі глікогену | |
| EA201270256A1 (ru) | Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида | |
| TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
| MX384131B (es) | Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos. | |
| EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
| UY34595A (es) | Composición farmacéutica de liberación prolongada de trimetazidina |